Obsidian Therapeutics reports 67% response rate for amsoki-cel in advanced melanoma trial

• Obsidian Therapeutics will present updated amsoki-cel melanoma trial results at the SITC annual meeting on November 7, 2026.
• The experimental cell therapy produced durable tumor responses in patients whose advanced melanoma had progressed despite immune checkpoint inhibitor treatment.
• Pooled safety results showed no treatment-related deaths or intensive care transfers; one severe case of cytokine release syndrome occurred.
• Enrollment in the registration-enabling cohort is expected to finish by the first quarter of 2027, with topline results due by year-end.
• Separate Phase 1 results evaluating amsoki-cel in non-small cell lung cancer are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Obsidian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261106751284) on November 06, 2026, and is solely responsible for the information contained therein.